Genus plc (LON:GNS – Get Free Report) crossed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of GBX 1,801.25 ($23.27) and traded as high as GBX 1,914 ($24.73). Genus shares last traded at GBX 1,901.92 ($24.58), with a volume of 5,376,931 shares traded.
Analysts Set New Price Targets
Separately, Shore Capital reiterated a “buy” rating on shares of Genus in a research report on Wednesday, December 11th.
View Our Latest Stock Report on GNS
Genus Price Performance
Genus (LON:GNS – Get Free Report) last announced its quarterly earnings results on Thursday, February 27th. The company reported GBX 39.80 ($0.51) EPS for the quarter. Genus had a return on equity of 1.41% and a net margin of 1.18%. On average, sell-side analysts expect that Genus plc will post 70.9644323 EPS for the current year.
Insider Transactions at Genus
In related news, insider Jorgen Kokke sold 19,967 shares of the company’s stock in a transaction that occurred on Friday, February 28th. The stock was sold at an average price of GBX 1,731 ($22.37), for a total value of £345,628.77 ($446,606.50). Corporate insiders own 0.75% of the company’s stock.
About Genus
Genus plc operates as an animal genetics company in North America, Latin America, the United Kingdom, rest of Europe, the Middle East, Russia, Africa, and Asia. The company operates through three segments: Genus PIC, Genus ABS, and Genus Research and Development. It sells breeding pigs and semen to breed pigs with various characteristics for pork production under the PIC brand.
Read More
- Five stocks we like better than Genus
- What is the S&P 500 and How It is Distinct from Other Indexes
- Institutional Investors Bet $1B on These 4 Stocks—Should You?
- 5 Top Rated Dividend Stocks to Consider
- One Must-Buy Stock and One to Avoid as Tariffs Shake the Market
- Overbought Stocks Explained: Should You Trade Them?
- These 4 Tech ETFs Just Hit 50-Day Lows—Time to Buy?
Receive News & Ratings for Genus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genus and related companies with MarketBeat.com's FREE daily email newsletter.